Abstract

ObjectiveExamine whether false-positive HIV enzyme immunoassay (EIA) test results occur more frequently among pregnant women than among women who are not pregnant and men (others).DesignTo obtain a large number of pregnant women and others tested for HIV, we identified specimens tested at a national laboratory using Genetic Systems HIV-1/HIV-2 Plus O EIA from July 2007 to June 2008.MethodsSpecimens with EIA repeatedly reactive and Western blot-negative or indeterminate results were considered EIA false-positive. We compared the false-positive rate among uninfected pregnant women and others, adjusting for HIV prevalence. Among all reactive EIAs, we evaluated the proportion of false-positives, positive predictive value (PPV), and Western blot bands among indeterminates, by pregnancy status.ResultsHIV prevalence was 0.06% among 921,438 pregnant women and 1.34% among 1,103,961 others. The false-positive rate was lower for pregnant women than others (0.14% vs. 0.21%, odds ratio 0.65 [95% confidence interval 0.61, 0.70]). Pregnant women with reactive EIAs were more likely than others (p<0.01) to have Western blot-negative (52.9% vs. 9.8%) and indeterminate results (17.0% vs. 3.7%) and lower PPV (30% vs. 87%). The p24 band was detected more often among pregnant women (p<0.01).ConclusionsFalse-positive HIV EIA results were rare and occurred less frequently among pregnant women than others. Pregnant women with reactive EIAs were more likely to have negative and indeterminate Western blot results due to lower HIV prevalence and higher p24 reactivity, respectively. Indeterminate results may complicate clinical management during pregnancy. Alternative methods are needed to rule out infection in persons with reactive EIAs from low prevalence populations.

Highlights

  • Universal screening to identify HIV infection in pregnant women is recommended so that infected women can be linked to care, start prophylaxis, plan for delivery, and avoid transmission through breastfeeding [1,2,3,4]

  • Alternative methods are needed to rule out infection in persons with reactive enzyme immunoassay (EIA) from low prevalence populations

  • Among all specimens with repeatedly reactive EIAs, we evaluated the proportion of specimens that were Western blotnegative, indeterminate, or positive, and the positive predictive value of the EIA test, by pregnancy status

Read more

Summary

Introduction

Universal screening to identify HIV infection in pregnant women is recommended so that infected women can be linked to care, start prophylaxis, plan for delivery, and avoid transmission through breastfeeding [1,2,3,4]. Screening is often conducted using a laboratory-based testing algorithm that incorporates enzyme immunoassays (EIAs) which have been approved by the Food and Drug Administration (FDA). These EIAs are highly sensitive and specific, but there is a perception that pregnant women are at higher risk for false-positive results [5,6]. False-positive HIV screening test results occur when a repeatedly reactive EIA is followed by a negative or indeterminate confirmatory test result in someone who is not infected. A person whose specimen exhibits a repeatedly reactive EIA and negative confirmatory test is likely not infected, and follow-up testing should be based on risk behaviors [7].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call